The main variables in a course of radiotherapy are the number of fractions, the dose per fraction, the total dose' given and the overall duration of treatment. Radiotherapists endeavour to employ a combination which will achieve the maximum tumour control with the minimum of normal tissue damage. At each centre in the United Kingdom regimes are employed in curative treatment that are based upon clinical experience, practical considerations and local tradition. Although,, in nearly all, daily treatment is given on five days of the week, the number of fractions ranges from 15 to 35, the individual dose from 1.8 to 3.4Gy, the total dose from 50 to 70 Gy and the overall duration from 3 to 7
weeks.
An accumulation of data from the laboratory and from the clinic now allows some explanation of the relationship between these variables (Withers et al., 1982 (Withers et al., , 1988 Trott & Kummermehr, 1984; Denekamp, 1986; Fowler, 1986; Tubiana, 1988) . In human tumours it has been possible to determine, using flow cytometry, not only the percentage of cells in S phase, but also the duration of S phase, and hence the potential doubling time, by giving an intravenous administration of bromodeoxyuridine 4-8 h before tumour sampling. Using this technique half of the human tumours studied showed a potential to double their cell number in 5 or fewer days (Begg et al., 1985 (Begg et al., , 1988 Wilson et al., 1985 Wilson et al., , 1988 . It is probable that the cells which survive the initial treatments of a course of radiotherapy will repopulate rapidly and replace those that have been killed. It follows that the longer the overall duration of treatment the greater must be the chance for repopulation to be a cause of failure. Turning to the normal tissues, we now know that the giving of a course of radiotherapy in many small individual doses may spare late damage, for injury to the critical supporting connective tissue is minimised under these conditions (Withers et al., 1982; Thames, 1988) . This knowledge may explain why different regimes may give similar tumour control and morbidity; however, it has also led to clinical exploration to develop new regimes which might bring a real advantage in tumour control.
In order to shorten the overall duration of radiotherapy and use a small individual dose per fraction, more than one treatment must be given on each day. There are now a number of completed and ongoing clinical studies using multiple treatments in one day and experience has already shown that a normal dose increment of 2 Gy cannot be maintained while giving accelerated treatment. There are problems with the tolerance of normal tissues and if a full tumour dose is given early reactions may not heal and will continue on to late morbidity (Peracchia & Salti, 1981 ; Van den Bogaert et al., 1982; .
To overcome this, many workers have interrupted their accelerated treatment in order to allow for normal tissue recovery (Van den Bogaert et al., 1982; Wang et al., 1986; . The rest periods have commonly been between 2 and 4 weeks but these, and also the weekend gap between the last treatment on Friday and the first on
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Monday, may allow considerable repopulation by surviving tumour cells to occur. A scheme of continuous, hyperfractionated, accelerated radiotherapy (CHART) was devised at Mount Vernon and took note of the biological data available (Saunders & Dische, 1986) . Radiotherapy was given three times daily for a continuous period of 12 days. As treatment was commenced on a Monday this required continuation through one weekend. The time interval between treatments given on each day was of considerable importance. If it were too short the maximum repair of sub-lethal injury in normal tissues would not have occurred and as a result some of the benefit would have been lost; based on laboratory data a period of 6 hours was chosen . A pilot study which included 128 patients was commenced in January 1985 and completed in December 1987. An individual dose of 1.4 Gy was given to the first 38 patients so that a total minimum tumour dose of 50.4Gy was achieved in the 36 treatments. As tolerance appeared good the individual dose was increased to 1.5 Gy so that the total dose given to the subsequent 90 patients was 54.0Gy (Saunders & Dische, 1989, and unpublished) .
Early radiation reactions have been well tolerated, but where the tongue has been included and the higher doses given, delays up to 6 months have occurred in a few cases before final healing. An interim assessment of late changes suggests that these may be less than after conventional treatment.
Included were 48 patients with advanced squamous cell cancer in the head and neck region who completed treatment. A complete regression was apparent in 44 (92%) of the 48 primary tumours and also in 18 (78%) of 23 patients who presented, in addition, secondary nodes. In an analysis performed in October 1988 concerning the 37 patients with T3 and T4 tumours when comparison was made with comparable previously treated cases at Mount Vernon there were statistically significant improvements in tumour control and survival (Saunders & Dische, unpublished) .
The results using CHART in 52 patients with locally advanced carcinoma of the bronchus were also compared with a previously treated group of 62 patients with similar disease. Using CHART complete radiological disappearance of tumour was obtained in 22 (42%) of the 52 patients compared with 9 (15%) of the 62 patients in the previous group. A review of the data in September 1988 showed that 30 (67%) of 45 patients treated more than 1 year previously remained alive at I year; of 26 treated more than 2 years previously 11 (42%) were alive at the 2-year interval (Saunders & Dische, 1989) . These findings can be compared with 44 and 12% obtained in the previous study, where results were comparable with those commonly recorded when locally advanced bronchogenic carcinoma is treated by radiotherapy (Perez et al., 1982; Schaake-Konig et al., 1983) .
As a result of a joint Medical Research Council and Cancer Research Campaign initiative, supported by the D of H, the promise of the pilot study is now to be tested in multi-centre randomised trials in bronchial and in head and neck cancer. It is hoped that randomisation into the studies will begin early in 1989. If, in the phase III studies, CHART is shown to be superior to conventional radiotherapy then the result will have significance for the whole of oncology, as the capacity of human tumours to repopulate rapidly will have been confirmed. Advances should follow the reduction of the overall duration of management from initial surgery through to completion of radiotherapy and cytotoxic chemotherapy.
